Procanbid

Atrial Fibrillation, life-threatening ventricular arrhythmias, Supraventricular Arrhythmias + 1 more
Treatment
13 Active Studies for Procanbid

What is Procanbid

ProcainamideThe Generic name of this drug
Treatment SummaryA version of the drug procaine with fewer effects on the central nervous system.
Procainamide Hydrochlorideis the brand name
Procanbid Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Procainamide Hydrochloride
Procainamide
1976
29

Effectiveness

How Procanbid Affects PatientsProcainamide is a medicine used to create local or regional anesthesia, and also to treat ventricular tachycardia that happens during heart surgery, catheterization, myocardial infarction, digitalis toxicity, or other cardiac diseases. It works similarly to procaine and quinidine by reducing the excitement of the ventricle and increasing the stimulation threshold during diastole. However, it does not affect the sinoatrial node.
How Procanbid works in the bodyProcainamide blocks sodium channels to stop the flow of electricity in your nerves. This helps to numb the area, providing a local anesthetic effect.

When to interrupt dosage

The proposed measure of Procanbid is contingent upon the recognized condition, including Supraventricular Arrhythmias, Ventricular Tachycardia and life-threatening ventricular arrhythmias. The dosage varies as per the administration strategy (e.g. Capsule, gelatin coated or Injection, solution - Intramuscular; Intravenous) featured in the table beneath.
Condition
Dosage
Administration
Atrial Fibrillation
, 500.0 mg/mL, 100.0 mg/mL, 500.0 mg, 375000.0 mg, 250.0 mg, 375.0 mg, 750.0 mg, 1000.0 mg
, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Intramuscular; Intravenous, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral
life-threatening ventricular arrhythmias
, 500.0 mg/mL, 100.0 mg/mL, 500.0 mg, 375000.0 mg, 250.0 mg, 375.0 mg, 750.0 mg, 1000.0 mg
, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Intramuscular; Intravenous, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral
Supraventricular Arrhythmias
, 500.0 mg/mL, 100.0 mg/mL, 500.0 mg, 375000.0 mg, 250.0 mg, 375.0 mg, 750.0 mg, 1000.0 mg
, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Intramuscular; Intravenous, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral
Ventricular Tachycardia
, 500.0 mg/mL, 100.0 mg/mL, 500.0 mg, 375000.0 mg, 250.0 mg, 375.0 mg, 750.0 mg, 1000.0 mg
, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Intramuscular; Intravenous, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

Procanbid Contraindications
Condition
Risk Level
Notes
Lupus
Do Not Combine
Complete Heart Block
Do Not Combine
Torsades de Pointes
Do Not Combine
There are 20 known major drug interactions with Procanbid.
Common Procanbid Drug Interactions
Drug Name
Risk Level
Description
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Artemether.
Asenapine
Major
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Asenapine.
Clofarabine
Major
The serum concentration of Clofarabine can be increased when it is combined with Procainamide.
Dalfampridine
Major
The serum concentration of Dalfampridine can be increased when it is combined with Procainamide.
Procanbid Toxicity & Overdose RiskThe lowest toxic dose of the drug in rats when administered intravenously is 95mg/kg, while in mice it is 312mg/kg when administered orally and 103mg/kg when administered intravenously. In rabbits, the lowest toxic dose is 250mg/kg when administered intravenously.

Procanbid Novel Uses: Which Conditions Have a Clinical Trial Featuring Procanbid?

17 active clinical trials are currently examining the potential of Procanbid to treat Ventricular Tachycardia, life-threatening ventricular arrhythmias and pre-excited atrial fibrillation.
Condition
Clinical Trials
Trial Phases
Ventricular Tachycardia
13 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Early Phase 1
life-threatening ventricular arrhythmias
0 Actively Recruiting
Atrial Fibrillation
0 Actively Recruiting
Supraventricular Arrhythmias
0 Actively Recruiting

Procanbid Reviews: What are patients saying about Procanbid?

5Patient Review
2/19/2008
Procanbid for Heart Ventricle Rhythm Problem
3Patient Review
3/15/2010
Procanbid for Osteoporosis
This treatment really helped me. I'm grateful for modern medicine.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about procanbid

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is another name for procainamide?

"PRONESTYL is a medication indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that are considered life-threatening by a physician."

Answered by AI

What is procainamide given for?

"Procainamide is administrated as an injection in order to treat irregular heartbeats and to slow an overactive heart. The heart will work more efficiently when it has a normal heartbeat (rhythm). Procainamide works by slowing the nerve impulses in the heart and reducing the sensitivity of heart tissues."

Answered by AI

What are the side effects of procainamide?

"The most common side effects of Pronestyl are nausea, vomiting, loss of appetite, diarrhea, and bitter taste in the mouth. Other side effects include dizziness, tiredness, flushinh, itching or rash."

Answered by AI

What class of drug is procainamide?

"Procainamide is a medication that is used to manage and treat various types of arrhythmias. It is a Class 1A antiarrhythmic agent."

Answered by AI

Clinical Trials for Procanbid

Have you considered Procanbid clinical trials? We made a collection of clinical trials featuring Procanbid, we think they might fit your search criteria.Go to Trials
Image of Medical University of Michigan in Ann Arbor, United States.

AI-Guided Ablation for Ventricular Tachycardia in Heart Disease

18+
All Sexes
Ann Arbor, MI
Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise estimation of lesion depth and quality when ablating VAs. AI guidance has previously been shown to improve outcomes in atrial and ventricular ablation in patients with premature ventricular complexes (PVC). However research on outcomes following AI-guidance for VT ablation specifically in patients with structural disease and prior myocardial infarction remains sparse. The investigators aim at conducting the first randomized controlled trial testing for the superiority of an AI-guided approach regarding procedural duration.
Recruiting
Has No Placebo
Medical University of Michigan (+5 Sites)Alexander Mazur, MDBiosense Webster, Inc.
Image of CardioVascular Associates of Mesa in Mesa, United States.

CCM Device for Heart Failure

18+
All Sexes
Mesa, AZ
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced left ventricular ejection fraction (LVEF ≤40%). Eligible subjects will be implanted with the CCM-D System. A subset of subjects will be induced into ventricular fibrillation "on the table" in the implant procedure room. During the follow-up period, inappropriate shock rate and device-related complications will be evaluated. The follow-up period is expected to last at least two years.
Waitlist Available
Has No Placebo
CardioVascular Associates of Mesa (+66 Sites)Niraj Varma, MD, PhDImpulse Dynamics
Have you considered Procanbid clinical trials? We made a collection of clinical trials featuring Procanbid, we think they might fit your search criteria.Go to Trials
Image of Nova Scotia Health Authority in Halifax, Canada.

SBRT for Ventricular Tachycardia

Any Age
All Sexes
Halifax, Canada
Ventricular tachycardia (VT) contributes to over 350,000 sudden deaths each year in the US. Malignant VTs involve an electrical "short circuit" in the heart, formed by narrow channels of surviving tissue inside myocardial scar. Current treatment for VT consists of either implantable defibrillators (ICDs), suppressive drug therapy, catheter ablation or a combination of all 3. Implantable Defibrillators (ICDs) reduce sudden death and can terminate some ventricular tachycardia (VT) without shocks, but they don't prevent VT. The occurrence of ≥1 ICD shock is associated with reductions in mental well-being and physical functioning, and increases in anxiety and sometimes depression. Further, ICD shocks have been consistently associated with adverse outcomes, including heart failure and death. Furthermore, the most important predictor of ICD shocks is a history of prior ICD shocks. Therapies to suppress VT include antiarrhythmic drug therapy and catheter ablation, neither however is universally effective. When VT recurs despite antiarrhythmic drug therapy and catheter ablation, novel yet invasive, approaches may be required. Such invasive procedures carry consequent risks of cardiac and extra-cardiac injury. Stereotactic body radiotherapy (SBRT) is a non-invasive technique that delivers high doses of radiation precisely to specified regions in the body, while minimizing exposure to adjacent tissue. This technique is currently, and commonly used in the treatment of cancer. Conventional application of SBRT has made use of its ability to spare non-target tissue, including for treatment of tumors near the heart. More recently, clinicians have changed the paradigm, by focusing radioablative energy on ventricular scar responsible for ventricular tachycardia. Pre-clinical studies have supported the concept and were followed by first-in-human VT therapeutic experience in 2017. Subsequent studies have had encouraging results for patients who failed or were unable to tolerate conventional treatment.
Recruiting
Has No Placebo
Nova Scotia Health AuthorityJohn Sapp, MD FRCPC
Image of QEII HSC in Halifax, Canada.

Electrophysiological Imaging for Ventricular Tachycardia

18 - 85
All Sexes
Halifax, Canada
Ventricular tachycardia (VT) contributes to over 350,000 sudden deaths each year in the US. Malignant VTs involve an electrical "short circuit" in the heart, formed by narrow channels of surviving tissue inside myocardial scar. An important treatment is to use catheter ablation to "block" the channel that forms the circuit. Effective ablation requires imaging guidance to visualize the VT circuit relative to scar structures in 3D. Unfortunately, with conventional catheter mapping, up to 90% of the VT circuits are too short-lived to be mapped. For the 10% "mappable" VTs, their data are only available during ablation and limited to one ventricular surface. This inadequacy of functional VT data largely limits the knowledge about scar-related VT and ablation strategies, and reduces the ability of clinicians to identify ablation targets and assess ablation outcome. The central hypothesis of this proposal is that functional VT data, integrated with CT or MRI scar data in 3D, can improve VT ablation efficacy with pre-procedural identification of ablation targets and post-procedural mechanistic elucidation of ablation failure. This research builds on the rapidly increasing clinical interest in electrocardiographic imaging (ECGi), an emerging technique that obtains cardiac electrical activity through inverse reconstructions from ECGs. The specific objective is to push the boundary of ECGi to provide - as a conjunction to intra-procedural catheter mapping - pre-ablation and post-ablation imaging of functional VT circuits integrated with 3D scar structure.
Recruiting
Has No Placebo
QEII HSCJohn L Sapp, MD FRCPC
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security